ImmunityBio (IBRX) Total Debt (2014 - 2026)

ImmunityBio (IBRX) has reported Total Debt for 12 consecutive years, with $404.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt rose 36.46% year-over-year to $404.3 million; the TTM figure through Mar 2026 stood at $404.3 million (up 36.46% YoY), while the FY2025 annual figure was $324.6 million, up 14.14% from the prior year.
• Total Debt improved to $404.3 million in Q1 2026 per IBRX's latest filing, from $324.6 million in the prior quarter.
• Across five years, Total Debt topped out at $480.0 million in Q3 2023 and bottomed at $108.8 million in Q2 2024.
• Historically, Total Debt has averaged $279.5 million across 5 years, with a median of $307.0 million in 2025.
• Annual changes were most pronounced in 2024 — Total Debt slumped 76.85% — and 2025, when it surged 184.45%.
• ImmunityBio's Total Debt stood at $373.3 million in 2022, then sank by 58.37% to $155.4 million in 2023, then soared by 83.0% to $284.4 million in 2024, then rose by 14.14% to $324.6 million in 2025, then advanced by 24.55% to $404.3 million in 2026.
• Business Quant data shows IBRX's Total Debt at $404.3 million in Q1 2026, $324.6 million in Q4 2025, and $316.1 million in Q3 2025.